Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Steven Davids, M.D.

Co-Author

This page shows the publications co-authored by Matthew Davids and Jennifer Crombie.
Connection Strength

2.236
  1. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017 Dec; 92(12):1393-1397.
    View in: PubMed
    Score: 0.757
  2. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017 Jun; 13(14):1223-1232.
    View in: PubMed
    Score: 0.746
  3. A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
    View in: PubMed
    Score: 0.238
  4. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
    View in: PubMed
    Score: 0.222
  5. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.
    View in: PubMed
    Score: 0.216
  6. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
    View in: PubMed
    Score: 0.057
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.